The price of Karyopharm Therapeutics Inc (NASDAQ: KPTI) closed at $1.39 in the last session, down -11.71% from day before closing price of $1.58. In other words, the price has decreased by -$0.1850 from its previous closing price. On the day, 1068935 shares were traded. KPTI stock price reached its highest trading level at $1.5600 during the session, while it also had its lowest trading level at $1.3800.
Ratios:
We take a closer look at KPTI’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.32 and its Current Ratio is at 3.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on January 19, 2023, initiated with a Overweight rating and assigned the stock a target price of $8.
On November 04, 2022, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform and also upped its target price recommendation from $7 to $10.
JP Morgan Upgraded its Underweight to Neutral on February 09, 2022, while the target price for the stock was maintained at $8.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 05 ’24 when Paulson Richard A. sold 3,573 shares for $1.30 per share. The transaction valued at 4,645 led to the insider holds 1,160,836 shares of the business.
Paulson Richard A. sold 19,374 shares of KPTI for $23,249 on Mar 01 ’24. The President and CEO now owns 1,164,409 shares after completing the transaction at $1.20 per share. On Mar 01 ’24, another insider, Mason Michael, who serves as the EVP, CFO & Treasurer of the company, sold 6,162 shares for $1.20 each. As a result, the insider received 7,394 and left with 398,756 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KPTI now has a Market Capitalization of 160.52M and an Enterprise Value of 146.09M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.10. Its current Enterprise Value per Revenue stands at 1.00 whereas that against EBITDA is -1.23.
Stock Price History:
Over the past 52 weeks, KPTI has reached a high of $4.87, while it has fallen to a 52-week low of $0.62. The 50-Day Moving Average of the stock is 1.2764, while the 200-Day Moving Average is calculated to be 1.2331.
Shares Statistics:
According to the various share statistics, KPTI traded on average about 1.77M shares per day over the past 3-months and 939.92k shares per day over the past 10 days. A total of 114.92M shares are outstanding, with a floating share count of 105.69M. Insiders hold about 8.15% of the company’s shares, while institutions hold 66.39% stake in the company. Shares short for KPTI as of Mar 15, 2024 were 23.13M with a Short Ratio of 13.06, compared to 23.43M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 20.10% and a Short% of Float of 20.45%.
Earnings Estimates
The company has 7 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.33 for the current quarter, with a high estimate of -$0.28 and a low estimate of -$0.37, while EPS last year was -$0.3. The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.27 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$1.09 and -$1.33 for the fiscal current year, implying an average EPS of -$1.23. EPS for the following year is -$1.01, with 7 analysts recommending between -$0.77 and -$1.27.
Revenue Estimates
According to 6 analysts, the current quarter’s revenue is expected to be $34.47M. It ranges from a high estimate of $38.36M to a low estimate of $31.7M. As of the current estimate, Karyopharm Therapeutics Inc’s year-ago sales were $36.6M, an estimated decrease of -5.80% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $36.42M, a decrease of -3.10% over than the figure of -$5.80% in the same quarter last year. There is a high estimate of $39.4M for the next quarter, whereas the lowest estimate is $34.6M.
A total of 6 analysts have provided revenue estimates for KPTI’s current fiscal year. The highest revenue estimate was $150.84M, while the lowest revenue estimate was $142.44M, resulting in an average revenue estimate of $146.52M. In the same quarter a year ago, actual revenue was $146.03M, up 0.30% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $164.74M in the next fiscal year. The high estimate is $209.72M and the low estimate is $130.2M. The average revenue growth estimate for next year is up 12.40% from the average revenue estimate for this year.
